重组人红细胞生成素在恶性肿瘤贫血中的应用  

The application of recombinant human erythropoietin in anemia associated with malignancy

作　　者：杨婉华[1] 王常玉[1] 王世宣[1] 卢运萍[1] 朱涛[1] 马丁[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院妇产科,430030

出　　处：《中国妇产科临床杂志》2002年第2期81-84,共4页Chinese Journal of Clinical Obstetrics and Gynecology

摘　　要：目的 评价重组人红细胞生成素(rHuEPO)治疗恶性肿瘤贫血的疗效。方法 首先体外应用rHuEPO对5例正常人和5例恶性肿瘤贫血患者骨髓做红系集落形成单位(CFU—E)培养。将45例妇科恶性肿瘤患者分治疗组23例和对照组22例做临床观察。结果 体外实验表明,在大剂量rHuEPO作用下,肿瘤患者骨髓CFU—E数明显增加,接近正常。临床观察治疗组血红蛋白(HGB)从用药第2周开始升高,而对照组HGB逐渐降低。rHuEPO每周应用169.69±38.82 U/kg的有效率为72.2％。结论rHuEPO是治疗恶性肿瘤相关贫血的有效药物。Objective To evaluate the effectiveness of recombinant human erythropoietin (rHuEPO) in anemia associated with malignancy.Methods Ten bone marrow samples including five cases of normal and five cases of anemia associated with malignancy were studied in vitro by culturing colony forming unit - erythroid CFU - E) with rHuEPO stimulating. Forty five patients with gynecologic oncology were enrolled onto clinical study, which were divided into study group with twenty three cases and control group with twenty two cases. Results The CFU - E of bone marrow from malignant group increased obviously and matched the results of normal group after large dose of rHuEPO stimulating. In clinical study, hemoglobin of patients in study group increased at two weeks after application of rHuEPO, whereas hemoglobin decreased progressively in most control cases. Effectiveness rate of rHuEPO was 72.2% in average dose of (169.69±38.82) U/kg/wk.Conclusions The rHuEPO is an effective drug in the treatment of anemia associated with malignancy.

关 键 词：红细胞生成素 集落形成单位 红系 贫血 恶性肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]